Katrina H. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katrina H. Lee has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Jennifer L. Hsiao
Department of Dermatology Keck School of Medicine, University of Southern California Los Angeles California USA
6 shared publicationsClaire S. Chung
Keck School of Medicine, University of Southern California, Los Angeles, USA
4 shared publications- Jennifer Lin Hsiao
Department of Dermatology University of Southern California Los Angeles California USA
3 shared publications Kenan Kherallah
Keck School of Medicine, University of Southern California, Los Angeles, USA
3 shared publicationsRaveena Ghanshani
Keck School of Medicine of USC, University of Southern California, Los Angeles, USA
3 shared publicationsSarah E. Park
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
3 shared publications
Latest Publications
- 8 October 2026
- Published by Wiley in Pediatric Dermatology
Impact of Biologic Therapy on Emergency Department Utilization in Pediatric Hidradenitis Suppurativa Patients
Hidradenitis suppurativa (HS) is a chronic inflammatory condition that often begins in adolescence and is associated with substantial morbidity and increased healthcare utilization, including emergency department (ED) visits. Using the TriNetX Global Network, a retrospective cohort study was conducted comparing pediatric HS patients who received biologic therapy before adulthood with biologic‐naïve pediatric HS controls. Biologic exposure was associated with a lower cumulative incidence of 1 or more all‐cause ED visits at 5 years (RR: 0.75, 95% CI: 0.58–0.97; p = 0.0250), 10 years (RR: 0.65, 95% CI: 0.51–0.84; p = 0.0002), and at any time after index (RR: 0.61, 95% CI: 0.48–0.77; p < 0.0001; NNT, 10). These findings suggest that biologic exposure during pediatric years is associated with lower subsequent all‐cause ED utilization among patients with HS.
- 8 October 2026
- Published by Wiley in Pediatric Dermatology
Impact of Biologic Therapy on Emergency Department Utilization in Pediatric Hidradenitis Suppurativa Patients
Hidradenitis suppurativa (HS) is a chronic inflammatory condition that often begins in adolescence and is associated with substantial morbidity and increased healthcare utilization, including emergency department (ED) visits. Using the TriNetX Global Network, a retrospective cohort study was conducted comparing pediatric HS patients who received biologic therapy before adulthood with biologic‐naïve pediatric HS controls. Biologic exposure was associated with a lower cumulative incidence of 1 or more all‐cause ED visits at 5 years (RR: 0.75, 95% CI: 0.58–0.97; p = 0.0250), 10 years (RR: 0.65, 95% CI: 0.51–0.84; p = 0.0002), and at any time after index (RR: 0.61, 95% CI: 0.48–0.77; p < 0.0001; NNT, 10). These findings suggest that biologic exposure during pediatric years is associated with lower subsequent all‐cause ED utilization among patients with HS.
- Open Access
- 29 September 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (11) , 5265-5283
Management Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review
- 29 September 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (11) , 5265-5283
Open AccessManagement Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review
- Open Access
- 3 December 2025
- Published by Springer Nature in Current Dermatology Reports
- Vol. 14 (1) , 35
Exploring the Pathophysiology, Burden, and Management of Itch in Hidradenitis Suppurativa: A Narrative Review
Purpose of Review: This narrative review explores the current understanding of itch in hidradenitis suppurativa (HS), a common yet underrecognized symptom that contributes significantly to patient burden. Herein, we summarize HS-associated itch pathophysiology, clinical impact, and management. Recent Findings: Emerging evidence indicates that itch affects more than half of patients with HS and arises from a complex interplay of immune dysregulation, mast cell activation, neural sensitization, and local irritation. Specific inflammatory markers such as IL-17, IL-31, and CCL-26 potentially play a role in itch pathogenesis. The degree of HS-associated pruritus correlates with disease severity, pain, drainage, and impaired quality of life. Recent studies suggest that topical clindamycin, strontium cream, bimekizumab, brodalumab, apremilast, povorcitinib, remibrutinib, and fostamatinib may improve HS-associated pruritus. Summary: Itch significantly contributes to HS disease burden yet often remains underassessed in clinical care. Standardized measurement tools and targeted therapies are needed to improve patient outcomes and guide future research.
- 3 December 2025
- Published by Springer Nature in Current Dermatology Reports
- Vol. 14 (1) , 35
Open AccessExploring the Pathophysiology, Burden, and Management of Itch in Hidradenitis Suppurativa: A Narrative Review
Purpose of Review: This narrative review explores the current understanding of itch in hidradenitis suppurativa (HS), a common yet underrecognized symptom that contributes significantly to patient burden. Herein, we summarize HS-associated itch pathophysiology, clinical impact, and management. Recent Findings: Emerging evidence indicates that itch affects more than half of patients with HS and arises from a complex interplay of immune dysregulation, mast cell activation, neural sensitization, and local irritation. Specific inflammatory markers such as IL-17, IL-31, and CCL-26 potentially play a role in itch pathogenesis. The degree of HS-associated pruritus correlates with disease severity, pain, drainage, and impaired quality of life. Recent studies suggest that topical clindamycin, strontium cream, bimekizumab, brodalumab, apremilast, povorcitinib, remibrutinib, and fostamatinib may improve HS-associated pruritus. Summary: Itch significantly contributes to HS disease burden yet often remains underassessed in clinical care. Standardized measurement tools and targeted therapies are needed to improve patient outcomes and guide future research.
- Open Access
- 13 November 2025
- Published by Springer Nature in Current Dermatology Reports
- Vol. 14 (1) , 31
Hidradenitis Suppurativa Flare Management: a Review of Medical and Procedural Strategies
Purpose of Review: While flares are a well-recognized feature of hidradenitis suppurativa (HS), defining flares and selecting an appropriate management strategy can be challenging. This narrative review discusses approaches to HS flare identification and management, highlighting both preventive and therapeutic strategies. Recent Findings: For decades, topical and systemic antibiotics have been a mainstay of HS flare treatment due to their anti-inflammatory properties and quick onset. According to a 2024 survey of HS experts, trimethoprim-sulfamethoxazole and amoxicillin-clavulanate were the second and third most prescribed antibiotic monotherapy following tetracyclines, respectively. Preliminary evidence suggests that pairing amoxicillin-clavulanate with a prednisone taper may have potential for gaining rapid control of HS flares. Among topical treatments, clascoterone and ruxolitinib emerge as promising non-antimicrobial options for mild to moderate HS. Procedural strategies for flare management include intralesional steroids for acutely inflamed nodules or tunnels and punch incision and drainage for relief of painful abscesses. A survey study of 900 individuals with self-reported HS found that complementary and alternative medicine (CAM) interventions are perceived to be one of the most helpful tools for flare management. Summary: Flares have significant implications for the quality of life in patients with HS. In order to synergize anchor therapy of baseline disease with prompt control of flare activity, a multimodal approach of medical, procedural, and CAM interventions combined with trigger avoidance and patient education is critical.
- 13 November 2025
- Published by Springer Nature in Current Dermatology Reports
- Vol. 14 (1) , 31
Open AccessHidradenitis Suppurativa Flare Management: a Review of Medical and Procedural Strategies
Purpose of Review: While flares are a well-recognized feature of hidradenitis suppurativa (HS), defining flares and selecting an appropriate management strategy can be challenging. This narrative review discusses approaches to HS flare identification and management, highlighting both preventive and therapeutic strategies. Recent Findings: For decades, topical and systemic antibiotics have been a mainstay of HS flare treatment due to their anti-inflammatory properties and quick onset. According to a 2024 survey of HS experts, trimethoprim-sulfamethoxazole and amoxicillin-clavulanate were the second and third most prescribed antibiotic monotherapy following tetracyclines, respectively. Preliminary evidence suggests that pairing amoxicillin-clavulanate with a prednisone taper may have potential for gaining rapid control of HS flares. Among topical treatments, clascoterone and ruxolitinib emerge as promising non-antimicrobial options for mild to moderate HS. Procedural strategies for flare management include intralesional steroids for acutely inflamed nodules or tunnels and punch incision and drainage for relief of painful abscesses. A survey study of 900 individuals with self-reported HS found that complementary and alternative medicine (CAM) interventions are perceived to be one of the most helpful tools for flare management. Summary: Flares have significant implications for the quality of life in patients with HS. In order to synergize anchor therapy of baseline disease with prompt control of flare activity, a multimodal approach of medical, procedural, and CAM interventions combined with trigger avoidance and patient education is critical.
- Open Access
- 8 November 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 67, 155-157
Dual immunomodulator therapy with upadacitinib and bimekizumab in severe hidradenitis suppurativa: A case report
- 8 November 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 67, 155-157
Open AccessDual immunomodulator therapy with upadacitinib and bimekizumab in severe hidradenitis suppurativa: A case report
- Open Access
- 18 October 2025
- Published by Springer Nature in Current Dermatology Reports
- Vol. 14 (1) , 1-9
Digital Innovations in Hidradenitis Suppurativa: A Narrative Review
Hidradenitis suppurativa (HS) is a chronic dermatologic condition characterized by recurrent painful nodules, abscesses, and draining sinus tracts in the intertriginous areas and can significantly affect patients’ quality of life. On average, patients face a 10-year delay in diagnosis. Despite recent advances in the management of HS, this complex and heterogenous condition presents ongoing challenges for both patients and healthcare providers. Developments in telehealth, artificial intelligence (AI), and HS-specific mobile applications, have emerged as transformative tools in the management of HS with many patients having improved access to care and up to date information. Providers have also benefited from the development of digital tools to improve patient care and research. Herein, we review the current landscape and characterize developments in technology, particularly digital technology such as tele-dermatology and AI, and their effects on HS patient care, patient access, patient experience and HS research.
- 18 October 2025
- Published by Springer Nature in Current Dermatology Reports
- Vol. 14 (1) , 1-9
Open AccessDigital Innovations in Hidradenitis Suppurativa: A Narrative Review
Hidradenitis suppurativa (HS) is a chronic dermatologic condition characterized by recurrent painful nodules, abscesses, and draining sinus tracts in the intertriginous areas and can significantly affect patients’ quality of life. On average, patients face a 10-year delay in diagnosis. Despite recent advances in the management of HS, this complex and heterogenous condition presents ongoing challenges for both patients and healthcare providers. Developments in telehealth, artificial intelligence (AI), and HS-specific mobile applications, have emerged as transformative tools in the management of HS with many patients having improved access to care and up to date information. Providers have also benefited from the development of digital tools to improve patient care and research. Herein, we review the current landscape and characterize developments in technology, particularly digital technology such as tele-dermatology and AI, and their effects on HS patient care, patient access, patient experience and HS research.
- Open Access
- 20 August 2025
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 11 (3) , e223
Utilizing the Patient Health Questionnaire (PHQ-2) as a depression screening tool for patients with hidradenitis suppurativa
- 20 August 2025
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 11 (3) , e223
Open AccessUtilizing the Patient Health Questionnaire (PHQ-2) as a depression screening tool for patients with hidradenitis suppurativa
- Open Access
- 5 July 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 63, 81-83
New onset hidradenitis suppurativa and eruptive milia associated with gamma secretase inhibitor therapy in a patient with desmoid tumor: A case report
- 5 July 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 63, 81-83
Open AccessNew onset hidradenitis suppurativa and eruptive milia associated with gamma secretase inhibitor therapy in a patient with desmoid tumor: A case report
- Open Access
- 22 January 2025
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 5 (1) , 66-69
Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
The oral Janus kinase (JAK) inhibitor baricitinib is approved by the U.S. Food and Drug Administration for the treatment of alopecia areata (AA). We report a case of dual improvement of AA and immune thrombocytopenia (ITP) with oral baricitinib monotherapy, which may suggest linked autoimmune pathophysiology. In phase III clinical trials of baricitinib for AA, reports of rare adverse haematological events include neutropenia and anaemia. While a history of haematological comorbidities may raise concern for many clinicians when considering treatment with a JAK inhibitor, this clinical vignette suggests that baricitinib may be considered and safely administered in those with concomitant AA and ITP. A 56-year-old man with a history of AA, ITP and vitiligo presented to the clinic for relapse of his steroid-resistant hair loss which had previously been treated with tofacitinib. In consultation with the patient’s haematologist, baricitinib 2 mg daily was started with close platelet monitoring then doubled to 4 mg after platelets showed improvement at the 6-month follow-up. Fourteen months after initiating baricitinib, improvement in white and dark hair regrowth was observed, and platelets remained normal. Thus, baricitinib may be considered for the dual treatment of AA and ITP with regular platelet monitoring and co-management with haematology colleagues.
- 22 January 2025
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 5 (1) , 66-69
Open AccessDual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
The oral Janus kinase (JAK) inhibitor baricitinib is approved by the U.S. Food and Drug Administration for the treatment of alopecia areata (AA). We report a case of dual improvement of AA and immune thrombocytopenia (ITP) with oral baricitinib monotherapy, which may suggest linked autoimmune pathophysiology. In phase III clinical trials of baricitinib for AA, reports of rare adverse haematological events include neutropenia and anaemia. While a history of haematological comorbidities may raise concern for many clinicians when considering treatment with a JAK inhibitor, this clinical vignette suggests that baricitinib may be considered and safely administered in those with concomitant AA and ITP. A 56-year-old man with a history of AA, ITP and vitiligo presented to the clinic for relapse of his steroid-resistant hair loss which had previously been treated with tofacitinib. In consultation with the patient’s haematologist, baricitinib 2 mg daily was started with close platelet monitoring then doubled to 4 mg after platelets showed improvement at the 6-month follow-up. Fourteen months after initiating baricitinib, improvement in white and dark hair regrowth was observed, and platelets remained normal. Thus, baricitinib may be considered for the dual treatment of AA and ITP with regular platelet monitoring and co-management with haematology colleagues.
- 21 January 2025
- Published by Elsevier in Dermatologic Clinics
- Vol. 43 (2) , 317-330
Hidradenitis Suppurativa in Children
- 21 January 2025
- Published by Elsevier in Dermatologic Clinics
- Vol. 43 (2) , 317-330
Hidradenitis Suppurativa in Children